Patients stratified as low risk according to IIM subtype, autoantibody patterns, and clinical features—ASS, overlapping IIM-SARD-associated myositis, those testing positive for anti-SRP antibody, anti-Jo1 antibody, non-Jo1 ASS antibody, as well as those with myositis-associated antibodies (anti-PM-Scl, anti-Ku, anti-RNP, anti-SSA/Ro, anti-SSB/La), Raynaud’s phenomenon, arthritis, and ILD—should be better considered to be at a standard risk of IIM-related cancer. The gene discussed is SSB; the disease is arthritic joint disease.